Omburtamab
Identification
- Summary
Omburtamab is an anti-CD276 (B7-H3) antibody being investigated for use in various solid human tumours.
- Generic Name
- Omburtamab
- DrugBank Accession Number
- DB15635
- Background
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.1,2 Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.3
Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Omburtamab
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
CD276 (also known as B7-H3) is a member of the B7/CD28 immunoglobulin superfamily with possible co-stimulatory and co-inhibitory roles in T cell-mediated immunity.1 Despite low to absent expression on most healthy cells, CD276 is frequently highly expressed among solid human tumours.1,2 Omburtamab, a murine anti-B7-H3 antibody, and its humanized forms bind to the CD276 FG loop thought to be important in co-inhibitory functions.1,3 Omburtamab also facilitates direct antibody-directed cellular cytotoxicity (ADCC) of CD276-expressing tumour cells.1 Recent experiments using chimeric antigen receptor (CAR) T cells and bispecific killer cell engager (BiKE)-redirected natural killer cells demonstrated efficacy against NSCLC in vitro and in vivo.2 Hence, targeting CD276 appears to be an appealing option for overcoming immunotherapy blockade in solid tumours.
Target Actions Organism ACD276 antigen binderHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XQL6783S5T
- CAS number
- 1895083-75-6
References
- General References
- Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK: Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem. 2015 Dec 11;290(50):30018-29. doi: 10.1074/jbc.M115.679852. Epub 2015 Oct 20. [Article]
- Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q: Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021 Jan 29;14(1):21. doi: 10.1186/s13045-020-01024-8. [Article]
- Kaplon H, Muralidharan M, Schneider Z, Reichert JM: Antibodies to watch in 2020. MAbs. 2020 Jan-Dec;12(1):1703531. doi: 10.1080/19420862.2019.1703531. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Desmoplastic Small Round Cell Tumor (DSRCT) / Peritoneal Cancer / Peritoneal Carcinoma 1 1 Completed Other Brain Cancer / Brain Stem Gliomas 1 1 Withdrawn Treatment Diffuse Intrinsic Pontine Gliomas (DIPG) 1 1, 2 Terminated Treatment Childhood Medulloblastoma 1 1, 2 Withdrawn Treatment Adult Solid Tumor / Metastatic Malignant Neoplasm to the Leptomeninges 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binder
- Curator comments
- Omburtamab binds to the FG loop of CD276 (B7-H3).
- General Function
- May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling.
- Specific Function
- Signaling receptor binding
- Gene Name
- CD276
- Uniprot ID
- Q5ZPR3
- Uniprot Name
- CD276 antigen
- Molecular Weight
- 57235.005 Da
References
- Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK: Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem. 2015 Dec 11;290(50):30018-29. doi: 10.1074/jbc.M115.679852. Epub 2015 Oct 20. [Article]
Drug created at March 07, 2020 20:12 / Updated at November 27, 2021 01:19